Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Caduet | Amlodipine besylate/ atorvastatin calcium | Hypertension/ Dyslipidemia | List with clinical criteria and/or conditions | Complete | ||
| Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
| Somavert | Pegvisomant | acromegaly | Do not list | Complete | ||
| DuoTrav | Travoprost and timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
| Trosec | Trospium chloride | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
| VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | ||
| Fosavance | Alendronate sodium/cholecalciferol | Osteoporosis | Do not list | Complete | ||
| Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | Do not list | Complete |
Last Updated : May 1, 2024